Haemonetics Achieves CE Mark Certification for VASCADE MVP® XL
In a significant advancement for patient care and medical technology, Haemonetics Corporation has announced that its innovative vascular closure device, the VASCADE MVP® XL, has received CE Mark certification. This certification allows the company to enhance its reach within the European Union and other regions that acknowledge CE marking, providing new opportunities for improved vascular closure solutions.
The first procedures utilizing the VASCADE MVP XL system were successfully conducted in October by leading physicians across Germany, Italy, and the UK. Notable figures such as Prof. Christian H. Heeger from the Asklepios Clinic Altona in Hamburg, Germany, Prof. Claudio Tondo from the Centro Cardiologico Monzino in Milan, Italy, and Dr. Riyaz A. Kaba at Cromwell Hospital in London, UK, spearheaded these initial applications. This rollout marks an exciting phase for both healthcare providers and patients in the field of interventional cardiology.
The VASCADE MVP XL system has been designed to address the percutaneous closure of femoral venous access sites, drastically minimizing post-procedural recovery times. Compared to traditional closure methods, it reduces the time needed for ambulation, total post-procedure duration, time to hemostasis, and eligibility for discharge. Such efficiency enables same-day discharge for patients undergoing catheter-based procedures with specific sheath sizes.
This device stands out for its use of 58% more collagen combined with a 9% larger closure disc than its predecessor, the VASCADE MVP® system. This enhancement provides a robust closure solution for larger-bore procedures requiring 10-12F sheaths, such as cryoablation or Pulsed Field Ablation (PFA) procedures, in addition to Left Atrial Appendage Closure (LAAC).
Ken Crowley, Vice President and General Manager of Interventional Technologies at Haemonetics, expressed optimism regarding the VASCADE MVP XL’s impact, particularly in the U.S. market, where it has been pivotal in advancing interventional technologies. Crowley stated, “With CE Mark certification and the first cases completed in Europe, we look forward to significantly expanding our impact and commercial momentum in electrophysiology and interventional cardiology.”
Hailing its advantageous features, Prof. Dr. Christian H. Heeger noted the importance of the VASCADE MVP system in enhancing post-procedure care by facilitating quicker ambulation and the earlier discharge of suitable patients. He emphasized that the new VASCADE MVP XL system allows for the application of the same closure technology in procedures needing larger venous access confidently.
Haemonetics' vascular closure offering comprises not only the VASCADE MVP XL system but also the original VASCADE vascular closure system, tailored for “small-bore” femoral arterial and venous closures employing standard procedural sheaths of 5-6/7F, and the VASCADE MVP system for “mid-bore” femoral venous closures utilizing 6-12F inner diameter sheaths. Both of these systems are CE marked under the EU-MDR and equipped with proprietary collapsible disc technology alongside a resorbable collagen plug to ensure hemostasis.
About Haemonetics
Haemonetics Corporation is a distinguished global medical technology business committed to elevating the quality, effectiveness, and efficiency of healthcare worldwide. They offer a wide range of solutions, including apheresis technologies that prioritize safety and donor satisfaction, as well as medical devices engineered to optimize the handling of blood products. Their Interventional Technologies sector focuses on advanced vascular closure systems and sensor-guided technologies that enhance procedural effectiveness and improve patient experiences.
As the healthcare landscape continues to evolve, Haemonetics' achievements and innovations underscore their uncompromising commitment to patient care and medical advancement, fostering an era of improved outcomes for patients across the globe. For more information on Haemonetics and their comprehensive product offerings, please visit
Haemonetics' official website.